CTX Inc.
- Biotech or pharma, therapeutic R&D
CTX is a clinical-stage biotechnology company advancing regenerative cell therapies through proprietary stem- and immune-cell platforms. Our lead programme, CTX-220, is a neuro-regenerative NRPC (Neuronal Regeneration–Promoting Cell) therapy derived from tonsil MSCs using a feeder-free, GMP-compliant process. In a Phase 1 Charcot-Marie-Tooth (CMT) study (n=9; single intramuscular dose; 6-month follow-up), CTX-220 achieved 100% response with a −7.0 mean change in CMTNS at the lowest dose, showing 25-fold dose efficiency and twice the clinical benefit of peer programmes. A Phase 1 trial for diabetic polyneuropathy (DPN) is also underway. CTX is seeking partners for clinical co-development and translational expansion. As a follow-up, CTX is developing autologous and allogeneic iPSC-derived midbrain dopaminergic (mDA) cell therapies for Parkinson’s disease, based on a proprietary differentiation platform that has shown functional recovery and dopamine restoration in preclinical models.
Address
SeoulSouth Korea
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}